127404-67-5

Basic information

• Product Name: 4-(3-fluoro-phenyl)-but-3-enoic acid
• Synonyms: 4-(3-fluoro-phenyl)-but-3-enoic acid
• CAS NO: 127404-67-5
• Molecular Weight: 180.179
• Mol File: 127404-67-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-(3-fluoro-phenyl)-but-3-enoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-fluoro-phenyl)-but-3-enoic acid(127404-67-5)
• EPA Substance Registry System: 4-(3-fluoro-phenyl)-but-3-enoic acid(127404-67-5)

Safety Data

• Hazardous Substances Data: 127404-67-5(Hazardous Substances Data)

Upstream product

• 64-18-6 formic acid 
• 38340-15-7 (+/-)-1-(3'-fluorophenyl)prop-2-en-1-ol 
• 456-48-4 3-Fluorobenzaldehyde 
• 51114-94-4 (2-carboxyethyl)triphenylphosphonium bromide 
• 1117-71-1 methyl 4-bromocrotonate 
• 62942-25-0 (3-fluorophenyl)tri-n-butyltin 

Downstream Products

• 93742-85-9 5-fluoro-3,4-dihydronaphthalen-1(2H)-one 
• 2840-44-0 7-fluoro-3,4-dihydronaphthalen-1(2H)-one 
• 13790-88-0 7-fluoro-1-tetralone oxime 
• 70631-88-8 4-(3-fluorophenyl)butanoic acid 

Relevant articles and documents

Efficient Pd-Catalyzed Regio- and Stereoselective Carboxylation of Allylic Alcohols with Formic Acid

Formic acid is efficiently used as a C1 source to directly carboxylate allylic alcohols in the presence of a low loading of palladium catalyst and acetic anhydride as additive to afford β,γ-unsaturated carboxylic acids with excellent chemo-, regio-, and stereoselectivity. The reaction proceeds through a carbonylation process with in situ-generated carbon monoxide under mild conditions, avoiding the use of high-pressure gaseous CO. A bisphosphine ligand with a large bite angle (4,5-bis{diphenylphosphino}-9,9-dimethylxanthene, Xantphos) was found to be uniquely effective for this transformation. The regio- and stereoconvergence of this reaction is ascribed to the thermodynamically favored isomerization of the allylic electrophile in the presence of the palladium catalyst.

PYRIDAZINONE COMPOUNDS AS CALCILYTICS

Various calcilytic compounds and pharmaceutical compositions containing these compounds are disclosed. Calcilytic compounds are compounds capable of inhibiting calcium receptor activity. Methods for preparing calcilytic compounds, oral bioavailability of calcilytic compounds, and their use as calcium receptor antagonists are also disclosed.

Synthesis of 6/7-halotetralones

The title compounds were prepared from halobromobenzenes via a palladium catalysed coupling followed by cyclisation.